ADALIMUMAB

作品数:89被引量:153H指数:6
导出分析报告
相关领域:医药卫生更多>>
相关作者:施安国胡欣杜勤董向毅崔胜男更多>>
相关机构:上海第二医科大学附属仁济医院北京大学北京医院浙江大学医学院附属第二医院更多>>
相关期刊:《Chinese Medical Journal》《中华物理医学与康复杂志》《中国科技期刊数据库 科研》《中国医药生物技术》更多>>
相关基金:国家自然科学基金更多>>
-

检索结果分析

结果分析中...
选择条件:
  • 期刊=World Journal of Clinical Casesx
条 记 录,以下是1-4
视图:
排序:
Menstrual cycle abnormalities in women with inflammatory bowel disease and effects of biological therapy on gynecological pathology
《World Journal of Clinical Cases》2023年第21期4989-4995,共7页Vaidota Malinauskiene Anastasija Zuzo Valentina Liakina Edita Kazenaite Ieva Stundiene 
Inflammatory bowel disease(IBD)is a chronic condition that affects young individuals in their reproductive years.It may have long-term implications on their reproductive,sexual,and mental health.IBD has been related t...
关键词:Menstrual disorders Inflammatory bowel disease ADALIMUMAB INFLIXIMAB Anti-tumor necrosis factor-α 
Tislelizumab-related enteritis successfully treated with adalimumab:A case report被引量:1
《World Journal of Clinical Cases》2022年第28期10186-10192,共7页Na Chen Min-Jia Qian Ru-Hui Zhang Qi-Qi Gao Chao-Chao He Ya-Ke Yao Jian-Ying Zhou Hua Zhou 
BACKGROUND With programmed death-1(PD-1) inhibitors becoming the standard treatment for lung cancer,PD-1-related adverse reactions and treatment have gradually become prominent.CASE SUMMARY First reported case of tisl...
关键词:Tislelizumab ADALIMUMAB ENTERITIS Case report 
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease:A systematic review and meta-analysis
《World Journal of Clinical Cases》2022年第18期6091-6104,共14页Hua-Hua Yang Yi Huang Xu-Chun Zhou Ruo-Nan Wang 
BACKGROUND Adalimumab(ADA)and infliximab(IFX)are the cornerstones of the treatment of Crohn’s disease(CD).It remains controversial whether there is a difference in the effectiveness and safety between IFX and ADA for...
关键词:Crohn disease ADALIMUMAB INFLIXIMAB Clinical efficacy Adverse effects META-ANALYSIS 
Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
《World Journal of Clinical Cases》2022年第14期4327-4333,共7页Hala Najeeb Farah Yasmin Salim Surani 
The increasing incidence of inflammatory bowel disease(IBD)globally has redirected the healthcare system's focus towards safe and affordable pharmacological interventions.The inception of anti-tumor necrosis factor-α...
关键词:Inflammatory bowel disease BIOSIMILARS Anti-tumor necrosis factor INFLIXIMAB ADALIMUMAB Ulcerative colitis Chrons disease 
检索报告 对象比较 聚类工具 使用帮助 返回顶部